Valion Bio, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
On November 6, 2026, Valion Bio closed a financing tranche with 3i, LP: 3i purchased 700 Series B Preferred Shares and warrants to buy 21,539 common shares at $0.5182/share for $700,000 aggregate. The Series B Preferred Purchase Agreement termination date was extended from December 9, 2026 to December 9, 2027. 3i also holds a $13.637M Series C position and a $16.25M convertible note.
Why this rating
At $4M market cap, $700K closing plus $23.86M Series C option represents meaningful capital runway. Extension signals investor confidence and sustained fundraising ability.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.54 ▲ 0.00% | at our read · unknown $0.54 | +10 min · unknown $0.53 ▼ 1.85% | +30 min · unknown $0.54 ▼ 0.76% | +1 hr · unknown $0.54 ▼ 0.72% | +4 hrs · unknown $0.53 ▼ 1.30% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.